A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

• Main Authors: Pin Zhang (Author), Binghe Xu (Author), Lin Gui (Author), Wenna Wang (Author), Meng Xiu (Author), Xiao Zhang (Author), Guilan Sun (Author), Xiaoyu Zhu (Author), Jianjun Zou (Author)
• Format: Book
• Published: BMC, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Dalpiciclib (SHR6390) is a novel inhibitor of cyclin-dependent kinase 4/6 which demonstrated promising anti-tumor potency in preclinical models. This first-in-human study was conducted to evaluate the tolerability, pharmacokinetics, safety, and preliminary antitumor activity of d...